NCT05824065尚未招募3 期
Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
EMS1 个研究点 分布在 1 个国家目标入组 504 人开始时间: 2025年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 504
- 试验地点
- 1
- 主要终点
- Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.
研究概览
简要总结
The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;
- •Age greater than 18 and equal or under 50 years;
- •Confirmed diagnosis of female pattern hair loss, grade II to IV in Sinclair Scale;
- •Participants that are disposed to maintain the same hair color, style, approximate hair length throughout the Clinical Study.
排除标准
- •Any clinical or physical finding interpreted by the investigator as a risk to subject participation in the Clinical Study
- •History of alcohol or illicit drugs abuse in the last year;
- •Pregnant or breastfeeding women, who are planning to become pregnant or participants who have childbearing potential and are not using any reliable contraceptive method;
- •Allergy or sensibility to any knowing components of the formula;
- •Diagnosis of arterial hypertension;
- •History of vasovagal syncope;
- •Baseline systolic blood pressure lower than 90 mmHg and/or diastolic lower than 60 mmHg;
- •Diagnosis of orthostatic hypotension (reduction of systolic blood pressure equal or superior to 20 mmHg and/or diastolic equal or superior to 10 mmHg after 3 minutes in orthostatic position);
- •Body mass index (BMI) > 30 kg/m²;
- •Subjects that initiated any kind of continue use medication, including contraceptives with systemic effect, until 3 months previously the inclusion in the Clinical Study;
- •History of cardiovascular, liver and renal diseases;
- •History of hypothyroidism, hyperthyroidism or pheochromocytoma;
- •Signs or symptoms of cardiopathy or angina;
- •History of edema from any etiology;
- •Participants who are using tricycle antidepressants, benzodiazepines, antipsychotics, anticholinergics, sulfonamide derivatives, beta-blockers, sympathomimetics, arginine, glucocorticoid or monoamine oxidase inhibitors;
- •Use of inhibitor of 5-alpha reductase or androgenic blockers in the last 12 months;
- •Dermatologic diseases of the scalp, except mild seborrheic dermatitis or diagnosis of any kind of alopecia other than female pattern hair loss;
- •History of surgical treatment for hair loss or presence of shaved scalp;
- •Scalp microinfusion, microneedling or intradermotherapy in the last 3 years;
- •Vaginal or cesarean deliveries 6 months before the inclusion in the study;
- •Drastic modification of habitual diet, as food restrictions or hyperselectivity;
- •Current cancer or history of cancer in the last 5 years;
- •Participation in others research protocols in the last 12 months, unless the investigator judges that there may be a direct benefit to the participant.
研究组 & 干预措施
Placebo
Placebo Comparator
Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
干预措施: Placebo (Drug)
OMA102 1 mg
Experimental
Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
干预措施: OMA102 (Drug)
OMA102 2 mg
Experimental
Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
干预措施: OMA102 (Drug)
结局指标
主要结局
Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.
时间窗: 6 months
Variation of hair in the mid-front area after 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.
次要结局
- Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.(3 months)
- Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception.(3 and 6 months)
- Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL).(3 and 6 months)
- Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Patient Global Impression, PGI-I, by the subject perception.(3 and 6 months)
- Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of non vellus and vellus hair growth, in the mid frontal area, assessed by digital phototrichogram.(3 and 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationIntraocular Lens ReplacementNCT01454063Omeros Corporation405
已完成
3 期
Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationIntraocular Lens ReplacementNCT01579565Omeros Corporation416
已完成
2 期
CAMB/MAT2203 in Patients With Mucocutaneous CandidiasisCandidiasis, Chronic MucocutaneousNCT02629419Matinas BioPharma Nanotechnologies, Inc.4
进行中（未招募）
2 期
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerNon Small Cell Lung Cancer MetastaticNCT05117242Genmab125
已完成
2 期
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)Multidrug Resistant TuberculosisNCT01859923Otsuka Pharmaceutical Development & Commercialization, Inc.37